東陽光藥：中期報告2022.pdf

《東陽光藥：中期報告2022.pdf》由会员分享，可在线阅读，更多相关《東陽光藥：中期報告2022.pdf（98页珍藏版）》请在三个皮匠报告上搜索。

1、CONTENTS目錄2Financial Highlights財務摘要3Corporate Profile公司簡介6Management Discussion and Analysis管理層討論及分析46Corporate Governance and Other Information企業管治及其他資料55Review Report審閱報告57Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表58Consolidated Statement of Financial Posit

2、ion綜合財務狀況表60Consolidated Statement of Changes in Equity綜合權益變動表62Condensed Consolidated Cash Flow Statement簡明綜合現金流量表63Notes to the Unaudited Interim Financial Report未經審核中期財務報告附註93Corporate Information公司資料YICHANG HEC CHANGJIANG PHARMACEUTICAL CO.,LTD./INTERIM REPORT 20222Financial Highlights財務摘要(RMB00

3、0)（人民幣千元）Six months ended 30 June 2022截至二零二二年六月三十日止六個月Six months ended 30 June 2021截至二零二一年六月三十日止六個月Year ended 31 December截至十二月三十一日止年度 2021202020192018二零二一年二零二零年二零一九年二零一八年 Revenue營業額1,293,308202,246913,7882,348,1136,224,024 2,510,476Gross profit毛利960,657100,788483,6991,996,5665,302,202 2,111,667Profi

4、t/(loss)from operations經營溢利（虧損）100,611(468,906)(423,377)1,254,6402,473,556 1,103,742(Loss)/profit before taxation除稅前（虧損）溢利(36,402)(588,204)(667,184)1,010,4342,269,053 1,102,324(Loss)/profit attributable to equity shareholders of the Company本公司權益股東 應佔（虧損）溢利(32,798)(507,028)(587,649)839,4551,918,709 9

5、42,536(Losses)/earnings per share (RMB cent)每股（虧損）盈利（人民幣分）Basic 基本(4)(58)(67)95216104 Diluted 攤薄(4)(58)(67)53207104Total assets總資產10,813,7218,913,67310,541,5819,561,2679,912,3394,560,940Total liabilities總負債4,825,4214,316,9914,520,8194,457,6085,289,184882,012Net assets淨資產5,988,3004,596,6826,020,7625,

6、103,6594,623,1553,678,928Profitability盈利能力Gross profit margin毛利率74.3%49.8%52.9%85.0%85.2%84.1%Operating profit margin經營溢利率7.8%-231.9%46.3%53.4%39.7%50.4%Net profit margin淨利潤率-2.5%-250.7%64.3%35.7%30.6%35.9%3Corporate Profile公司簡介中期報告2022 /宜昌東陽光長江藥業股份有限公司宜昌東陽光長江藥業股份有限公司（以下簡稱 本公司或 東陽光藥，連同其附屬公司統稱 本集團）是一